Literature DB >> 25131320

Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients.

A C Ford1, N J Talley, M M Walker, M P Jones.   

Abstract

BACKGROUND: There is increasing evidence that impaired mucosal defence mechanisms are implicated in the pathogenesis of the functional gastrointestinal disorders (FGIDs), allowing inappropriate immune activation. AIM: To test the hypothesis that an excess of autoimmune disorders among sufferers, using a large primary care database to examine this.
METHODS: Cases were diagnosed with FGIDs - irritable bowel syndrome (IBS), functional dyspepsia (FD), chronic idiopathic constipation (CIC), and multiple FGIDs. Controls were those without FGIDs. Prevalence of autoimmune disorders was compared between cases and controls using odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: We included 23,471 patients (mean age 51.4 years, 66.1% female). Prevalence of autoimmune disorders was greater among all FGIDs, compared with controls without. In those with FD (OR 1.35; 95% CI 1.12-1.63), CIC (OR 1.75; 95% CI 1.11-2.75), or multiple FGIDs (OR 1.49; 95% CI 1.25-1.77) this was statistically significant after controlling for age and gender. Rheumatological autoimmune disorders were significantly more frequent in those with FD (OR 1.44; 95% CI 1.15-1.80), CIC (OR 1.84; 95% CI 1.08-3.13), or multiple FGIDs (OR 1.53; 95% CI 1.24-1.88), after controlling for age and gender. However, endocrine autoimmune disorders were no more frequent in those with FGIDs, after controlling for age and gender.
CONCLUSIONS: In a large sample of primary care patients, there was a significantly higher prevalence of autoimmune disorders among those with FD, CIC, or multiple FGIDs not explained by differences in age or gender. We were unable to control for concomitant drug use, which may partly explain this association.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25131320     DOI: 10.1111/apt.12903

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

Review 1.  The mucosal immune system: master regulator of bidirectional gut-brain communications.

Authors:  Nick Powell; Marjorie M Walker; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 46.802

Review 2.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 3.  Functional dyspepsia: new insights into pathogenesis and therapy.

Authors:  Nicholas J Talley
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

Review 4.  Functional Dyspepsia: Advances in Diagnosis and Therapy.

Authors:  Nicholas J Talley
Journal:  Gut Liver       Date:  2017-05-15       Impact factor: 4.519

5.  Functional gastrointestinal disorders negatively affect health-related quality of life in MS.

Authors:  Ruth Ann Marrie; Stella Leung; Tuula Tyry; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2019-10

6.  An exploration into the motivation for gluten avoidance in the absence of coeliac disease.

Authors:  Lucy Harper; Justine Bold
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

7.  Joint Hypermobility Syndrome in Patients With Functional Dyspepsia.

Authors:  Florencia Carbone; Asma Fikree; Qasim Aziz; Jan Tack
Journal:  Clin Transl Gastroenterol       Date:  2020-11       Impact factor: 4.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.